Lung cancer screening with low-dose CT (LDCT) has well-established mortality benefits, yet real-world uptake and adherence remain major challenges. Health systems have implemented specific requirements—such as shared decision-making (SDM) visits—to improve patient engagement and sustain annual screening. But does this approach actually influence whether patients continue screening over time? This question sits at the intersection of policy, patient behavior, and clinical outcomes.